#ESMO21 Highlights on adagrasib in patients with KRASG12C-mutated CRC: The KRYSTAL-1 study

Jared Weiss reports on key results from ESMO Congress 2021 on LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or in Combination With Cetuximab in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation

19 Sep 2021  Presidential symposium 2

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.